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A B S T R A C T
The fundamental objective for health research is to determine whether changes should be
made to clinical decisions. Decisions made by veterinary surgeons in the light of new
research evidence are known to be inﬂuenced by their prior beliefs, especially their initial
opinions about the plausibility of possible results. In this paper, clinical trial results for a
bovine mastitis control plan were evaluated within a Bayesian context, to incorporate a
community of prior distributions that represented a spectrum of clinical prior beliefs. The
aim was to quantify the effect of veterinary surgeons’ initial viewpoints on the
interpretation of the trial results.
A Bayesian analysis was conducted using Markov chain Monte Carlo procedures.
Stochastic models included a ﬁnancial cost attributed to a change in clinical mastitis
following implementation of the control plan. Prior distributions were incorporated that
covereda realistic rangeofpossibleclinicalviewpoints, including scepticism,enthusiasmand
uncertainty. Posterior distributions revealed important differences in the ﬁnancial gain that
clinicianswith different starting viewpoints would anticipate from themastitis control plan,
given the actual research results. For example, a severe scepticwould ascribe a probability of
0.50 for a return of<£5 per cow in an average herd that implemented the plan, whereas an
enthusiast would ascribe this probability for a return of >£20 per cow. Simulations using
increased trial sizes indicated that if the original study was four times as large, an initial
sceptic would be more convinced about the efﬁcacy of the control plan but would still
anticipate less ﬁnancial return than an initial enthusiast would anticipate after the original
study. In conclusion, it is possible to estimate how clinicians’ prior beliefs inﬂuence their
interpretation of research evidence. Further research on the extent to which different
interpretations of evidence result in changes to clinical practice would be worthwhile.
 2009 Elsevier B.V.
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Open access under CC BY license. health interventions in populations and clinical manage-
ment of individual patients. Results from such research are
of greatest value when ﬁndings translate into improve-
ments in health and welfare. For new research to be
worthwhile in terms of changing clinical decisions, the
clinical beliefs (‘clinical priors’) of the decision-makers
need to be understood and taken into account. This is
important because the inferences made by each individual
in the light of a particular clinical trial will be inﬂuenced by
their prior beliefs or degree of scepticism about the
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Rhame, 2001; Spiegelhalter et al., 2004a). Whilst it is
important to note that an individual clinician’s decision to
change their approach to disease control is complex (and
may depend on a variety of psychological and circum-
stantial factors, as well as the perceived cost or health
beneﬁt (Crosskerry, 2005)), investigation of the inﬂuence
of prior beliefs is an important element of understanding
this decision process.
The fact that there are prior beliefs in medicine is well
documented (e.g. Fallowﬁeld et al., 1997; Peto and Baigent,
1998; Spiegelhalter et al., 2004a; Henry et al., 2006). Such
beliefs have been used to predict and understand the
decision making process of medical physicians (Parmar
et al., 1994; Brophy and Joseph, 1995; Harrell and Shih,
2001). Documenting prior beliefs before undertaking
clinical trials is useful to gauge the likely response of
clinicians to possible trial outcomes (and therefore
whether clinical decision-making will change) and also
to aid in sample size calculations—the strength of evidence
required differs depending on the degree of scepticism at
the outset (Kadane, 1994; Parmar et al., 1994; Chaloner
and Rhame, 2001). However, prior distributions are not
necessarily pre-speciﬁed or unique and can be used post
hoc, to assess how research results may be interpreted,
conditional on varying personal viewpoints (Spiegelhalter
et al., 2004a).
In veterinary medicine, little is known of the hetero-
geneity in clinical beliefs of veterinary surgeons, although
this will fundamentally affect interpretation of research
evidence and approaches to disease management. The use
of a ‘community of priors’ has been proposed by Kass and
Greenhouse (1989) to describe a spectrum of realistic
viewpoints that should be considered when interpreting
new evidence.
Bayesian methods are particularly suited to the
incorporation of prior beliefs in a probabilistic decision-
theoretic context (Berry and Stangl, 1996; O’Hagan and
Luce, 2003) and have some advantages over frequentist
approaches that include the following, a straightforward
framework for predicting future events and the ability to
include information, with associated uncertainty, from a
variety of sources (Berry, 1993; Spiegelhalter et al.,
2004a).
The purpose of the current research was to re-evaluate
the results of a clinical trial for a control plan for bovine
mastitis (Green et al., 2007). A community of priors was
incorporated, within a Bayesian context, to represent a
spectrum of prior opinions of clinicians. The aim of the
research was to assess the variability in clinical inter-
pretation that could arise from veterinary surgeons with
different prior viewpoints.
2. Method
2.1. Description of the original clinical trial
The original research comprised a randomised clinical
trial for a mastitis control plan on 52 dairy herds and has
been described in detail in Green et al. (2007). A brief
outline of the methods and results is presented here. InJanuary 2004, a database administered by National Milk
Records (NMR, Chippenham, UK) was used to identify
and randomly select dairy herds with a recorded
incidence rate of clinical mastitis >35 cases per 100
cows during the previous 12 months. Selection was made
from herds situated throughout England and Wales.
Herds were randomly allocated to one of two groups. The
ﬁrst group had an intervention—a mastitis control plan
implemented (this was a holistic control scheme devised
from research literature) whilst the second group were
treated as control herds. The ﬁrst stage of the control plan
was to assess the patterns and types of mastitis in each
herd. The second stage was to compare existing farm
control measures with those in the control plan to
highlight the measures not used by the farmer. A level of
importance was attached to each control measure to
determine a priority for implementation and a set of up to
20 ﬁnal recommendations were made to each farmer in
the intervention group. Compliance with the control plan
was measured and estimated as the proportion of
recommendations made that were actually implemented
by the farmer during the 1 year study period. A simple
categorisation was used for compliance, this was a score
of one given when less than one-third of recommenda-
tions were applied, two when between one and two-
thirds were applied and three when greater than two-
thirds were applied.
A response variable used to assess efﬁcacy of the
control plan was the change in incidence rate of clinical
mastitis between year 1 (the 12 months before the
intervention was carried out) and year 2 (the 12 months
following the date of intervention) expressed as a
proportion of the year 1 incidence rate of clinical
mastitis. The null hypothesis for the study was that
there would be no difference in the change in incidence
rate of clinical mastitis between intervention farms that
implemented the plan (n = 26) and control farms that did
not (n = 26). The alternative hypothesis was that there
would be a difference between treatment groups in the
mean proportional change of clinical mastitis of 0.20
and conventional sample size estimates were under-
taken with a power set at 0.8 and signiﬁcance
probability at 0.05. The original analysis was conducted
within a frequentist framework and the relevant results
were as follows:1. Proportional change in incidence rate of clinical mastitis
for intervention herds versus control herds = 0.20
(SE = 0.09), p < 0.05.2. Proportional change in incidence rate of clinical mastitis
for compliance score 3 herds versus control
herds = 0.39 (SE = 0.14), p < 0.01.
2.2. Bayesian models
The two models from which these results were
calculated in the original study were replicated using
the same data, and placed within a Bayesian framework
with speciﬁcation of prior distributions for model para-
meters. Model parameter posterior distributions were
estimated using Markov chain Monte Carlo using the
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et al., 2004b).
The models considered for the current analysis were
Model 1:
yi ¼ b0 þ b1IFi þ b2IRCMyr1i þ e1i
e1iNð0;s2e1Þ
Model 2:
yi ¼ b0 þ b3C3i þ b4C2i þ b5C1þ b6IRCMyr1i þ e2i
e2iNð0;s2e2Þ
where yi: proportional change in incidence rate of clinical
mastitis in herd i; b0: model intercept; IFi: covariate to
identify intervention farms,; b1: coefﬁcient representing the
mean proportional change in incidence rate of clinical
mastitis for intervention herds compared to control herds.;
IRCMyr1i: covariate to account for starting incidence rate of
clinical mastitis in herd i; b2 and b6: coefﬁcients for year 1
IRCM; C3i, C2i, C1i: covariates for herds of compliance
categories 3, 2 and 1 respectively compared to control herds.;
b3,b4 andb5: coefﬁcients for compliance categories 3, 2 and 1
respectively.; e1i and e2i: residual terms to reﬂect unex-
plained variation between herds with variance s2e1 and s
2
e2 in
Models 1 and 2, respectively.
Models were run with three Markov chains and the
effect of different chain starting values on model para-
meters was investigated but not found to inﬂuence
posterior estimates. Model convergence was examined
using informal visual assessment of the chains (Gilks et al.,
1996) and the Gelman–Rubin convergence diagnostic
(Brooks and Gelman, 1998). All of the MCMC analyses
reported in the current paper used a burn-in of at least
2000 iterations and all models convergedwell ahead of the
end of this burn-in. Analysis was then based on an
additional 20,000 iterations.
2.3. Prior distributions
A range of Gaussian prior distributions were assessed
for the ﬁxed effect parameters b0, b2, b4, b5 and b6, to
investigate their inﬂuence on b1 (Model 1) and b3 (Model
2). Gaussian distributions were investigated with a meanTable 1
Descriptions of the prior distributions for b1 incorporated into Model 1 to repr
mastitis control plan.
Name of prior Distribution (mean, SD) Description of view rep
Vague Normal (0, 100) No view or ability to m
therefore prepared to en
Very sceptic Normal (0, 0.05) A mean effect size of 0
in mastitis more than 
Sceptic Normal (0, 0.10) A mean effect size of 0
in mastitis more than 
Mid sceptical
enthusiastic
Normal (0.1, 0.10) A mean effect size of 0
in mastitis greater than
Cautious sceptic Mixture: Normal (0, 0.10) 
0.80 + Normal (0, 0.5)  0.20
A weighted mixture of a
probability) to reﬂect a
belief is incorrect and to
Enthusiastic Normal (0.2, 0.10) A mean effect size of 0
in mastitis less than 0.
Very enthusiastic Normal (0.3, 0.05) A mean effect size of 0
in mastitis less than 0of 0.5, 0, or 0.5 and a variance of 10,000 or 0.25. No
substantive differences were identiﬁed in model results
and the distribution (mean = 0, variance = 10,000) was
used for the ﬁnal models. Several alternative priors for the
distributions of e1i and e2i were investigated (Uniform (0,
5) or Uniform (0, 1) for the standard deviations or inverse
Gamma (0.01, 0.01) for the variances) but the choice had
little effect on the other parameter estimates and Uniform
(0, 5) priors were used in the ﬁnal models. Six different
prior distributionswere incorporated for the coefﬁcients of
interest, b1 (Model 1) and b3 (Model 2); the aim was to
choose priors that would cover a realistic and reasonable
range of clinical opinion and that could represent views
sensibly held by clinicians. This community of priors is
described in Tables 1 and 2.
2.4. Financial evaluation
To further elucidate possible differences in interpreta-
tion of the clinical trial data between clinicians with
different prior beliefs, a ﬁnancial evaluation was carried
out as follows. Models were extended to include a ﬁnancial
gain (or loss) attributed to the anticipated change in
clinical mastitis (£s per cow in the herd per year)
conditional on the clinical trial data and the prior
distributions. The estimated cost of a case of clinical
mastitis was based on a recent publication of disease costs
in UK dairy herds (Esslemont and Kossaibati, 2002). The
mean estimated cost per case was a combination of
treatment costs (including veterinary time), herdsman
time, discarded milk, reduced subsequent milk yield,
severity of disease and risk of culling or death (Esslemont
and Kossaibati, 2002). Milk price has recently increased in
the UK, however, and there is currently some variation
between farms. Therefore a distribution for milk price was
included in the calculation, based on current prices, with a
mean of £0.25/l and standard deviation of £0.01/l. Other
ﬁnancial values remained as originally reported (Essle-
mont and Kossaibati, 2002). The resultant cost of a case of
clinical mastitis was normally distributed with mean
£212.30 and standard deviation £5.44. The ﬁnancial gain
anticipated from implementing the control plan on a herd
with an assumed incidence rate of clinical mastitis of 0.5esent a range of clinical viewpoints on the probable effectiveness of the
resented
ake a choice as to what the likely parameter values could be and
compass a very large possible range.
with a 2.5% probability that the effect size could be a reduction
0.10
with a 2.5% probability that the effect size could be a reduction
0.20
.10 with a 15% probability that the effect size could be a reduction
0.20 or less than 0.
sceptical prior (80% probability) and a more cautious prior (20%
sceptical who is prepared to allow a 20% probability that their sceptical
widen the standard deviation of the effect size by a factor of ﬁve.
.20 with a 2.5% probability that the effect size could be a reduction
.30 with a 2.5% probability that the effect size could be a reduction
.20.
Table 2
Descriptions of the prior distributions for b3 incorporated into Model 2 to represent a range of clinical viewpoints on the probable effectiveness of the
mastitis control plan.
Name of prior Distribution (mean, SD) Description of view represented
Vague Normal (0, 100) No view or ability to make a choice as to what the likely parameter values could be and
therefore prepared to encompass a very large possible range.
Very sceptic Normal (0, 0.05) A mean effect size of 0 with a 2.5% probability that the effect size could be a reduction in
mastitis more than 0.10
Sceptic Normal (0, 0.15) A mean effect size of 0 with a 2.5% probability that the effect size could be a reduction in
mastitis more than 0.30
Mid sceptical
enthusiastic
Normal (0.15, 0.15) A mean effect size of 0.10 with a 15% probability that the effect size could be a reduction in
mastitis greater than 0.20 or less than 0.
Cautious sceptic Mixture: Normal (0, 0.15) 
0.80 + Normal (0, 0.75)  0.20
A weighted mixture of a sceptical prior (80% probability) and a more cautious prior (20%
probability) to reﬂect a sceptical who is prepared to allow a 20% probability that their sceptical
belief is incorrect and to widen the standard deviation of the effect size by a factor of ﬁve.
Enthusiastic Normal (0.3, 0.15) A mean effect size of 0.30 with a 2.5% probability that the effect size could be a reduction in
mastitis less than 0.
Very enthusiastic Normal (0.4, 0.05) A mean effect size of 0.40 with a 2.5% probability that the effect size could be a reduction in
mastitis less than 0.30.
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farms (Bradley et al., 2007)) was estimated from the
posterior (predictive) distribution of b1 (the proportional
reduction in clinical mastitis estimated fromModel 1) and
the cost per case of clinical mastitis:
Anticipated financial gain ð£sper cow in the herdper yearÞ
¼ b1  cost of mastitis ðNðmean ¼ 212:30; variance
¼ 25:59ÞÞ  0:5
The distribution of the anticipated ﬁnancial gain was
estimated for each prior distribution of b1 (Table 1), using
MCMC, by evaluating 20,000 iterations after model
convergence. To obtain an estimate for the ﬁnancial
returns anticipated in a fully complying herd, the
procedure was repeated using b3 and Model 2.
The probabilities of obtaining ﬁnancial returns greater
or equal to speciﬁed ﬁnancial levels (between £0 and 50
per cow in the herd per year) were estimated for each prior
distribution of b1 and b3. This was carried out within the
MCMC procedure as follows: at each iteration, an indicator
variable was set to 1 when the model predicted the
ﬁnancial return was greater than a speciﬁed value and
otherwise to 0. The mean value of this indicator over the
20,000 iterations after convergence provided an estimate
of the probability of exceeding the speciﬁed ﬁnancial
return, a method similar to that described for Monte Carlo
P values (Marshall and Spiegelhalter, 2003).
2.5. Investigations of posterior distributions and
simulations of increased trial sizes
The heterogeneity in the posterior distributions of b1
(Model 1) was further explored by including a wider
variety of combinations of values for both the prior mean
(range 0 to 0.3) and prior standard deviation (range
0.001–100). Modelling procedures were as described
above, and the mean posterior values for b1, for different
values of prior mean and standard deviation, were
displayed graphically.
MCMC simulations were carried out to predict the
possible effect of increasing the size of the original clinical
trial on the inferences of clinicianswith originally scepticalor originally enthusiastic prior beliefs. Simulations of
larger sized trials were conducted by replicating the
original dataset by a factor of two, three and four times.
Therefore, the distribution of the data and model
coefﬁcients remained the same but the uncertainty
associated with parameter estimates was reduced. Poster-
ior distributions for b1 were estimated for each simulated
trial of increased size, incorporating either a sceptical or
enthusiastic prior distribution for b1. The probability of
anticipated ﬁnancial changes attributed to changes in
clinical mastitis were calculated for each simulated trial, as
described in Section 2.4, and displayed graphically.
3. Results
3.1. Posterior distributions of b1 and b3
The posterior distributions of b1 from Model 1 are
presented in Table 3. With the inclusion of the vague prior
distribution for b1, the resulting posterior distribution had
very similar characteristics to the original frequentist
estimates for b1. The probabilities for an anticipated
ﬁnancial saving from a reduced incidence of clinical
mastitis were 0.85 for a return of at least £10 per cow
in the herd and 0.54 for a return of at least £20 per cow in
the herd. The sceptical prior resulted in a posterior mean
estimate for b1 of 0.10, half way between the sceptical
prior mean and the original frequentist estimate for b1,
indicating that a clinician with this sceptical viewpoint
would effectively discount the clinical trial results by
approximately 50% compared to the frequentist inter-
pretation of the data. The very sceptical prior was altered
very little by the trial data, the posterior mean of 0.04
being one-ﬁfth of the original frequentist estimate for b1
and thus these data would make only a small impact on a
clinician with such a large degree of scepticism. The
cautious sceptic (Table 1), would bemore convinced by the
trial results, the posterior mean estimate for b1 being
0.13. This was similar to the posterior mean of 0.15
estimated with a prior belief that b1 was at the mid-point
between the sceptical and enthusiastic priors. The
enthusiastic prior resulted in a similar mean posterior
estimate to the vague prior (0.20), but with a reduced
Table 3
Posterior distributions of b1 estimated fromModel 1 conditional on the speciﬁed prior distributions and the clinical trial data.
Name of prior Prior distribution Posterior distribution
Mean (SD) Mean (SD) 95% credibility interval
Vague 0 (100) 0.20 (0.10) 0.39 to 0.00
Very sceptic 0 (0.05) 0.04 (0.05) 0.13 to 0.05
Sceptic 0 (0.10) 0.10 (0.07) 0.25 to 0.04
Mid sceptical enthusiastic 0.10 (0.10) 0.15 (0.07) 0.30 to 0.01
Cautious sceptic 0 (0.13) 0.13 (0.08) 0.28 to 0.03
Enthusiastic 0.20 (0.10) 0.20 (0.07) 0.34 to 0.06
Very enthusiastic 0.30 (0.05) 0.28 (0.04) 0.37 to 0.19
Table 4
Posterior distributions of b3 estimated fromModel 2 conditional on the speciﬁed prior distributions and the clinical trial data.
Name of prior Prior distribution Posterior distribution
Mean (SD) Mean (SD) 95% Credibility interval
Vague 0 (100) 0.39 (0.14) 0.67 to 0.11
Very sceptic 0 (0.05) 0.04 (0.05) 0.13 to 0.05
Sceptic 0 (0.15) 0.21 (0.11) 0.41 to 0.00
Mid sceptical enthusiastic 0.15 (0.15) 0.28 (0.10) 0.49 to 0.07
Cautious sceptic 0 (0.19) 0.26 (0.12) 0.48 to 0.03
Enthusiastic 0.30 (0.15) 0.35 (0.10) 0.55 to 0.15
Very enthusiastic 0.40 (0.05) 0.40 (0.05) 0.49 to 0.31
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the posterior mean if this prior view was held. The
posterior mean for b1 estimated using a very enthusiastic
prior was 0.28 and thus remained closer to this prior
distribution mean than the original frequentist mean
estimate.
The characteristics for the posterior distributions of b3
estimated in Model 2 are presented in Table 4. Similar
patterns were identiﬁed between the different choices of
prior as for b1. It was particularly notable that whilst the
sceptical prior resulted in a posterior distribution indicat-
ing a reasonably large anticipated reduction in clinical
mastitis (posterior mean0.21, standard deviation = 0.11),
the original trial data would be insufﬁcient to convince
clinicians with views represented by the very sceptical
prior distributions, that the control plan would be very
effective, even in herds that fully complied (posterior
mean = 0.04, standard deviation = 0.05).
3.2. Financial evaluations
The anticipated ﬁnancial returns estimated from
Models 1 and 2 are presented in Figs. 1 and 2. Clinicians
with beliefs represented by any of the prior distributions,
except the very sceptical category, would anticipate a gain
of £10 in this ‘‘average’’ herd that undertook the control
plan with a probability of 0.50. The posterior probability
of a gain £10 varied from 0.55 for the sceptical prior
distribution to 0.99 for the very enthusiastic prior.
There was considerable variation in the posterior
probability of achieving a gain of at least £20 per cow in
the herd dependent on the different prior distributions.
The very sceptical prior resulted in a posterior probability
of virtually zero whereas the vague or enthusiastic priors
resulted in a posterior probability greater than 0.50. Aclinician with a view represented by the very enthusiastic
prior view would anticipate a gain £20 as being almost
certain with a probability approaching 1.0.
Taken as a whole, results from Model 1 (Fig. 1)
demonstrated that the probability of different ﬁnancial
gains varied greatly with different prior distributions. This
variability indicates that, in light of the clinical trial data,
clinicians could differ widely in their approach to
implementing the plan, some anticipating considerably
more ﬁnancial return than others.
The pattern of results was broadly similar when herd
compliance with the control plan was considered in Model
2 (Fig. 2), although with higher anticipated ﬁnancial
returns. Parameter estimates revealed that clinicians with
beliefs represented by any of the prior distributions, except
the very sceptical prior, would anticipate a 0.50 probability
of a gain ofmore than £22 per cow in a herd that undertook
and fully complied with the control plan, compared to a
non-participant. However, there was considerable varia-
bility in the anticipated probability of achieving minimum
gains in the region of £20–40 per cow in the herd (Fig. 2),
dependent on prior clinical beliefs, again indicating that
the trial data are likely to lead to different clinical
interpretations dependent upon different initial view-
points.
3.3. Further assessment of the prior distribution
characteristics
As illustrated in Fig. 3, the mean posterior value of b1
varied to a large extent with both the mean and standard
deviation of the prior distribution of b1. The posterior
mean tended towards the value of the prior mean as the
prior standard deviation decreased and tended towards
0.20 as the prior standard deviation increased. A given
Fig. 1. An illustration of the probability of the anticipated overall ﬁnancial gains from implementing the mastitis control plan estimated from Model 1,
conditional on speciﬁed prior distributions (Table 1) and the clinical trial data.
Fig. 2. An illustration of the probability of anticipated ﬁnancial gains from implementing the mastitis control plan on farms that fully comply, estimated
from Model 2, conditional on the speciﬁed prior distributions (Table 2) and the clinical trial data.
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from a prior distribution with a mean close to that
posterior mean (e.g. 0.15) with a relatively small
standard deviation, or from a prior mean closer to zero,
and a relatively larger standard deviation.
3.4. Simulations of increased sized trials
Simulations of anticipated ﬁnancial returns with
different theoretical sizes of trial are summarised in
Fig. 4. Simulations using the sceptical prior distributiondemonstrated that the anticipated ﬁnancial gain gradually
increased (curves moved to the right) and the variation of
the posterior distribution decreased (curves became
steeper) as trial size increased. However, the increase in
anticipated ﬁnancial gain became proportionately less as
the new data became less inﬂuential in comparison to the
existing information. With a clinical trial four times the
size of the original, an initial sceptic would consider that
there was a comparable probability (0.93) of a ﬁnancial
gain of at least £10 per cow in the herd, to an initial
enthusiast after the original sized clinical trial. However,
Fig. 3.Graphical illustration of the variation of the prior mean and standard deviation, and the posterior mean of b1, estimated fromModel 1, conditional on
the clinical trial data.
Fig. 4. An illustration of the probability of the anticipated overall ﬁnancial gains from implementing themastitis control plan estimated fromModel 1, using
the original trial data and three simulated trials of increased size that incorporated the sceptical prior (Table 1).
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initial sceptic would still attribute a lower probability
(0.28) than the initial enthusiast would attribute after the
original study (0.58), that a minimum gain of £20 per cow
would be achieved. Simulations of increased trial sizes
using the enthusiastic prior as the starting point (Fig. 5)
demonstrated that anticipated ﬁnancial gains would
change very little with the increased information, although
the clinician with this original belief would become more
certain of their anticipated ﬁnancial return with the
additional information.
4. Discussion
The results suggest that a clinician’s prior view will
make a fundamental impact on how the clinical trial data
for this mastitis control plan are interpreted. An initial
sceptic, when presented with this evidence would
anticipate a reduction in clinical mastitis approximately
half that of the initially enthusiastic clinician. This
translates into large differences in anticipated ﬁnancial
gains from reduced clinical mastitis, often in the region £5
and £20 per cow in the herd (Figs. 1 and 2). The differencesin clinical interpretation and anticipated ﬁnancial return
dependant on prior viewpoints are of a magnitude that
wouldmake importantmaterial differences in practice and
are likely to inﬂuence the assessment of when the plan is
cost effective and therefore recommended. The results also
illustrate why a conventional ‘signiﬁcant’ result may
provide an insufﬁcient strength of evidence to change
the clinical approaches of some more sceptical clinicians.
The costs of implementing thismastitis control planwill
varybetweenherdsdependingon themanagement changes
required (Green et al., 2007), but the annual costs are likely
to be in the region £5 to £50 per cow in the herd. For a 100
cowherd this equates to a variation in total implementation
costs of £500 to £5000 per annum, reﬂecting, for example,
differences between small changes to current management
or a capital investment with repayment over several years.
Therefore differences in anticipated ﬁnancial return of £5 to
£20 per cow, depending on a clinicians view, will be
important indeterminingwhether theplan is implemented,
and therefore could lead to different clinical decisions in the
same farm circumstances.
An individual clinician’s decision to change their
approach to disease control, however, is complex and will
Fig. 5. An illustration of the probability of the anticipated overall ﬁnancial gains from implementing themastitis control plan estimated fromModel 1, using
the original trial data and three simulated trials of increased size that incorporated the enthusiastic prior (Table 1).
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perceived cost or health beneﬁt. A rational decision has
been deﬁned as one that meets four criteria (Hastie and
Dawes, 2001): it is based on the decision makers current
state (physiological, psychological, ﬁnancial, social and
emotional), on the possible consequences of the choice, on
the logical probability of different outcomes and is adapted
according to the value placed on each possible outcome.
Therefore, the situation, cognitive dispositions and per-
sonality of a clinician will inﬂuence how decisions are
made (Crosskerry, 2005) and this means that individual
veterinary clinicians with the same prior beliefs and
presented with the same research evidence may make
different judgements. Factors such as the veterinary
surgeon-client relationship, the farm situation (such as
the ﬁnancial state), the value attributed to non-ﬁnancial
beneﬁts (such as cow welfare) will inﬂuence decision-
making alongside the current mastitis situation and
anticipated return on investment from implementing
the plan. Whilst different prior beliefs can greatly affect
the interpretation of a single piece of research evidence,
more research would be useful to investigate and quantify
other aspects of the decision processes in farm animal
health.
Results from the current study conﬁrm the importance
of both the magnitude (location) of a prior belief and the
certainty with which the view is held (Fig. 3). When the
certainty of a prior belief declines, the inﬂuence of the data
increases and the posterior mean tends towards the
likelihood of the data. Therefore, to assess a clinician’s
ﬁnal belief, in light of new evidence, it is important to
establish not only the central location of their prior view
but also the certainty with which it is held, and methods
have been described to elicit these quantities (O’Hagan
et al., 2006). The graph of different prior distribution
means and standard deviations in relation to subsequent
posterior distribution means (Fig. 3) illustrates priordistribution standard deviations varying from very small
(0.01) to relatively large (2.0). In reality, such extreme
clinical views would be unlikely. It seems improbable that
a clinician would have a belief with a 95% credibility
interval as small as 0.02 around the estimated mean (a
change inmastitis of only2% of the initial level). Similarly, a
prior standard deviation of 1.00 would mean that a clinician
was so uncertain that there was a 95% credibility interval of
approximately 2.00 around the mean effect (a change in
mastitis of200% of the initial level), this would appear to be
greater than could be reasonably anticipated. It is likely that
most clinical prior beliefs would have a standard deviation in
the region 0.05–.3 and thus the region of the graph (Fig. 3)
within this range probably contains the most realistic
representation of the relationship between plausible clinical
prior distributions and the posterior mean.
The vague prior distributions used in these analyses for
the ﬁxed effects b1 and b3 are often described as ‘‘non-
informative’’ or ‘‘reference’’ priors (Spiegelhalter et al.,
2004a) and often will result in a posterior distribution with
characteristics similar to the frequentist estimates (Gurrin
et al., 2000).However, it is hard to ascribe a realistic, rational
clinical meaning to this prior distribution since such an
uninformed viewwould seem to be almost impossible to be
held by a clinician. Therefore, whilst it is useful in terms of
allowing the data to have ‘‘an overriding inﬂuence’’ on the
posterior distribution, it is of limited value when trying to
evaluate the likely interpretation of clinicians in the ﬁeld.
Since Bayesian philosophy essentially concerns the updat-
ingof personal beliefs in the light of newevidence, theuseof
vague, unrealistic prior distributions has understandably
been questioned (Senn, 2007).
The value of assessing the effect of sceptical priors in
clinical trials is illustrated in the current study by the
important clinical differences that would arise in inter-
pretation of these mastitis trial data. Sceptical priors are
also useful to estimate sample sizes for clinical trials
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be common, then it is important to design a study that can
convince sufﬁcient members of the relevant population. In
the current study, simulations of clinical trials of increased
size identiﬁed that with more data, a clinician with an
initial sceptical view would gradually become more
convinced of the efﬁcacy of the control plan. If such a
sceptical view is very prevalent in the population of
veterinary surgeons, then larger studies would be impor-
tant to provide sufﬁcient evidence to convince these
clinicians that the control plan could be worthwhile.
Bayesian methods are particularly useful to calculate
probabilities that may be extrapolated directly to clinical
practice (Burton et al., 1998; Lilford et al., 1995) and this
research provides an illustration in veterinary medicine.
Although the testing of a variety of prior opinions in
Bayesian analyses has been strongly recommended to
demonstrate how new data would add to the range of
currently held views (Koch, 1991; Hughes, 1991; Spie-
gelhalter et al., 2004a) this type of analysis has been rarely
reported in the medical or veterinary literature. However,
it is necessary to understand clinical inferences and the
decision-making process, beyond simply providing new
evidence, if research is going to have a widespread impact
on animal health. This is particularly true in veterinary
medicine in which there is little overall national strategy
for many diseases of dairy cows and in which many
decisions on herd health are taken by individual practi-
tioners rather than being set by a general health policy.
Research to quantify the population structure of veterinary
beliefs for mastitis control and other aspects of herd health
management would be very welcome to improve the
understanding of the diversity of clinical approaches
exhibited by veterinary surgeons. Knowledge of the degree
and distribution of scepticism and enthusiasm would help
to inform future research both in terms of research areas
most needed and the strength of evidence that would be
necessary to convince clinicians that changing approaches
could be beneﬁcial.
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